TrialScientific reports2024

Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial.

Fabrice Bonnet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.